查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2067525

藥物發現平台市場規模、佔有率和趨勢分析報告：按藥物類型、應用、治療領域、最終用途、地區和細分市場預測（2026-2033 年）

Drug Discovery Platforms Market Size, Share & Trends Analysis Report By Drug Type, By Application, By Therapeutic Area, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 190 Pages | 商品交期: 2-10個工作天內

價格

藥物發現平台市場概述

全球藥物發現平台市場預計到 2025 年將達到 34 億美元，預計到 2033 年將達到 105 億美元，2026 年至 2033 年的複合年成長率為 15.1%。

推動這一市場成長的因素有很多，包括人工智慧 (AI) 和機器學習 (ML) 在藥物發現中的應用日益廣泛、製藥和生物技術領域的研發 (R&D) 投資不斷增加、對精準醫療和標靶治療的需求不斷成長，以及計算藥物發現技術的進步。

人工智慧和機器學習在藥物研發流程中的日益普及是推動市場成長的主要動力。基於人工智慧和機器學習的平台使製藥和生物技術公司能夠分析大規模生物資料集，識別潛在藥物靶點，並比傳統方法更快、更準確地最佳化先導化合物。這些技術支援虛擬篩檢、預測毒理學、分子建模和生成式藥物發現，從而降低研發成本並縮短分子發現時間。

此外，人工智慧驅動的自動化降低了臨床試驗失敗的風險，並提高了決策效率。對快速開發癌症和罕見疾病新療法的需求日益成長，進一步推動了整個製藥業對人工智慧藥物發現平台的採用。例如，2026年1月，皮爾法伯實驗室和Iktos宣佈建立人工智慧藥物發現合作夥伴關係，旨在透過結合計算設計、生物學、藥物化學、醫學和臨床前開發方面的能力，開發新型小分子癌症療法。

與 Iktos 的此次合作是皮爾法伯實驗室建構人工智慧驅動型研發引擎的重要里程碑。將 Iktos 的生成式人工智慧和自動化化學技術整合到我們的研究平台，標誌著我們朝著實現數據和人工智慧策略邁出了重要一步。此次合作體現了我們致力於利用前沿創新技術來提升藥物研發的品質和成功率，並加速為癌症患者帶來實際療效的承諾。

奧黛麗‧考夫曼，皮爾法伯醫療研發部資料科學與生物辨識技術主管

此外，對精準醫療和標靶治療日益成長的需求正在推動藥物發現平台市場的成長。精準醫療是指根據個人基因譜、生物標記和疾病特徵開發客製化治療方法。這促使人們採用人工智慧驅動的藥物發現、基因組學、生物資訊學和多體學技術。

藥物發現平台支援生物標記識別、分子譜分析和患者分層。這使得針對癌症、罕見疾病和神經系統疾病等疾病開發高度標靶且有效的治療方法成為可能。因此，製藥和生物技術公司正日益增加對基於精準醫療的藥物發現的投資和合作，從而推動市場成長。例如，2025年3月，BostonGene公司宣布與強生公司合作，利用人工智慧驅動的分子譜分析技術在臨床試驗中評估大腸直腸癌和多發性骨髓瘤的生物標記。

同樣，2024年8月，波士頓基因公司與武田製藥合作，利用人工智慧驅動的分子和免疫分析技術評估免疫療法。此次合作旨在透過先進的多組體學和生物資訊分析，改善患者篩選、識別治療反應和毒性的預測性生物標記物，並最佳化臨床試驗設計。這些合作旨在透過先進的分子分析，增強患者分層、最佳化治療方法選擇並識別預測性生物標記。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：藥物發現平台市場：變數、趨勢與範圍

  • 市場譜系展望
  • 產業價值鏈分析
  • 市場動態
  • 按應用程式概覽
  • 藥物發現平台的市場分析工具

第4章：藥物發現平台市場：依藥物類型分類的估算與趨勢分析

  • 按藥物類型分類的市場佔有率，2025 年和 2033 年
  • 全球藥物研發平台市場：依藥物類型分類，展望
  • 低分子
  • 聚合物化合物

第5章：藥物發現平台市場：按應用分類的估算與趨勢分析

  • 按應用領域分類的市場佔有率，2025 年和 2033 年
  • 全球藥物研發平台市場：依應用領域分類，展望
  • 目標識別
  • 目標驗證
  • 發現鉛
  • 先導藥物最適化
  • 臨床前試驗
  • 其他（包括臨床試驗）

第6章：藥物發現平台市場：依治療領域分類的估算與趨勢分析

  • 按治療區域分類的市場佔有率，2025 年和 2033 年
  • 全球藥物研發平台市場：依治療領域分類，展望
  • 腫瘤學
  • 神經病學
  • 心血管疾病
  • 感染疾病及免疫系統疾病
  • 消化器官系統疾病
  • 其他（呼吸系統疾病、糖尿病）

第7章：藥物發現平台市場：依最終用途分類的估算與趨勢分析

  • 按最終用途分類的市場佔有率，2025 年和 2033 年
  • 全球藥物發現平台市場：依最終用途分類，展望
  • 生物製藥公司
  • 學術研究機構
  • CRO／CDMO

第8章：藥物發現平台市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 區域市場概述
  • 市場規模、預測與趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 丹麥
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司和競爭對手的分類
  • 主要公司市佔率分析，2025 年（%）
  • 主要公司市場分析（2025 年）
  • 公司簡介
    • Schrodinger, Inc.
    • Certara
    • Optibrium Ltd
    • Insilico Medicine
    • Atomwise, Inc.
    • XtalPi Holdings Limited
    • Dassault Systemes SE
    • Genedata AG
    • Relay Therapeutics, Inc.
    • Recursion Pharmaceuticals, Inc.
    • Merck KGaA
    • insitro Inc.
Product Code: GVR-4-68040-916-6

Drug Discovery Platforms Market Summary

The global drug discovery platforms market size was estimated at USD 3.4 billion in 2025 and is projected to reach USD 10.5 billion by 2033, growing at a CAGR of 15.1% from 2026 to 2033. The market growth is driven by several factors, including the increasing adoption of artificial intelligence (AI) and machine learning in drug discovery, rising pharmaceutical and biotechnology R&D investments, growing demand for precision medicine and targeted therapies, and advances in computational drug discovery.

The increasing adoption of AI and Machine Learning (ML) in drug discovery workflows is significantly driving the growth of the market. AI and ML-based platforms enable pharmaceutical and biotechnology companies to analyze large biological datasets, identify potential drug targets, and optimize lead compounds with greater speed and accuracy compared to conventional methods. These technologies support virtual screening, predictive toxicology, molecular modeling, and generative drug design, thereby reducing R&D costs and the time to molecule discovery.

In addition, AI-driven automation reduces clinical trial failure risks and improves decision-making efficiency. The growing demand for faster development of novel therapeutics, such as oncology and rare diseases, is further encouraging the adoption of AI-powered drug discovery platforms across the pharmaceutical industry. For instance, in January 2026, Pierre Fabre Laboratories and Iktos announced a collaboration for AI-driven drug discovery, aimed at developing novel small-molecule oncology therapies by combining computational design, biology, medicinal chemistry, medical science, and preclinical development capabilities.

This collaboration with Iktos marks an important milestone in our journey to build an AI-powered R&D engine at Pierre Fabre Laboratories. By integrating Iktos' generative AI and automated chemistry technologies into our research platforms, we are taking a step toward realizing our data and AI strategy. This cooperation exemplifies our ambition to leverage cutting-edge innovation to improve the quality and probability of success in drug discovery, while accelerating the delivery of meaningful advances for patients in oncology.

Audrey Kauffmann, Head of Data Science and Biometry at Pierre Fabre Medical Care R&D

Moreover, the rising demand for precision medicine and targeted therapies supports the growth of the drug discovery platforms market. Precision medicine develops treatments tailored to individual genetic profiles, biomarkers, and disease characteristics. This increases the adoption of AI-enabled drug discovery, genomics, bioinformatics, and multiomics technologies.

Drug discovery platforms support biomarker identification, molecular profiling, and patient stratification. This enables the development of highly targeted and effective therapies for diseases such as cancer, rare disorders, and neurological conditions. Consequently, pharmaceutical and biotechnology companies are increasingly investing in and collaborating on precision medicine-based drug development, supporting market growth. For instance, in March 2025, BostonGene Corporation announced a collaboration with Johnson & Johnson to evaluate biomarkers for colorectal cancer and multiple myeloma using AI-driven molecular profiling in clinical trials.

Similarly, in August 2024, BostonGene Corporation partnered with Takeda Pharmaceutical to evaluate immunotherapies using AI-powered molecular and immune profiling technologies. The collaboration focuses on improving patient selection, identifying predictive biomarkers for treatment response and toxicity, and enhancing clinical trial design through advanced multiomics and bioinformatics analysis. These partnerships aim to enhance patient stratification, optimize treatment selection, and identify predictive biomarkers through advanced molecular analytics.

Global Drug Discovery Platforms Market Report Segmentation

This report forecasts revenue growth and provides at the global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global drug discovery platforms market report based on drug type, application, therapeutic area, end use, and region:

  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecule
  • Large Molecule
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Target Identification
  • Target Validation
  • Lead Discovery
  • Lead Optimization
  • Preclinical Testing
  • Other (including Clinical Trials)
  • Therapeutic Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Neurology
  • Cardiovascular Diseases
  • Infectious and Immune System Diseases
  • Digestive System Diseases
  • Other (Respiratory Diseases, Diabetes)
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • CROs/CDMO
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Type Segment
    • 1.1.2. Application Segment
    • 1.1.3. Therapeutic Area Segment
    • 1.1.4. End Use Segment
    • 1.1.5. Regional scope
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2
    • 1.9.3. Objective 3

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Type Outlook
    • 2.2.2. Application Outlook
    • 2.2.3. Therapeutic Area Segment
    • 2.2.4. End Use Outlook
    • 2.2.5. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Drug Discovery Platforms Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Industry Value Chain Analysis
    • 3.2.1. Reimbursement framework
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Increasing adoption of Artificial Intelligence (AI) and Machine Learning in drug discovery workflows
      • 3.3.1.2. Rising pharmaceutical and biotechnology R&D investments
      • 3.3.1.3. Growing demand for precision medicine and targeted therapies
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. High implementation and operational costs of advanced drug discovery platforms
      • 3.3.2.2. Data privacy, integration, and regulatory challenges associated with AI-driven drug discovery systems
    • 3.3.3. Market Opportunity Analysis
    • 3.3.4. Industry Challenge
  • 3.4. Application Overview
    • 3.4.1. Virtual Reality (VR) and Augmented Reality (AR)
    • 3.4.2. Artificial Intelligence (AI)
    • 3.4.3. Gamification
    • 3.4.4. Use of Multidisciplinary Approach in the Development of Simulators
    • 3.4.5. 3D Printing
  • 3.5. Drug Discovery Platforms Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Social landscape
      • 3.5.2.4. Economic landscape
      • 3.5.2.5. Legal landscape

Chapter 4. Drug Discovery Platforms Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Drug Discovery Platforms Market by Drug Type Outlook
  • 4.4. Small Molecule
    • 4.4.1. Small molecule market, 2021 - 2033 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large molecule market, 2021 - 2033 (USD Million)

Chapter 5. Drug Discovery Platforms Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Drug Discovery Platforms Market by Application Outlook
  • 5.4. Target Identification
    • 5.4.1. Target identification market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5. Target Validation
    • 5.5.1. Target validation market estimates and forecast 2021 to 2033 (USD Million)
  • 5.6. Lead Discovery
    • 5.6.1. Lead discovery market estimates and forecast 2021 to 2033 (USD Million)
  • 5.7. Lead Optimization
    • 5.7.1. Lead optimization market estimates and forecast 2021 to 2033 (USD Million)
  • 5.8. Preclinical Testing
    • 5.8.1. Preclnical tasting market estimates and forecast 2021 to 2033 (USD Million)
  • 5.9. Other (including Clinical Trials)
    • 5.9.1. Other (including clinical trial) market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Drug Discovery Platforms Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Therapeutic Area Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Drug Discovery Platforms Market by Therapeutic Area Outlook
  • 6.4. Oncology
    • 6.4.1. Oncology market estimates and forecast 2021 to 2033 (USD Million)
  • 6.5. Neurology
    • 6.5.1. Neurology market estimates and forecast 2021 to 2033 (USD Million)
  • 6.6. Cardiovascular Diseases
    • 6.6.1. Cardiovascular Diseases market estimates and forecast 2021 to 2033 (USD Million)
  • 6.7. Infectious and Immune System Diseases
    • 6.7.1. Infectious and immune system diseases market estimates and forecast 2021 to 2033 (USD Million)
  • 6.8. Digestive System Diseases
    • 6.8.1. Digestive system diseases market estimates and forecast 2021 to 2033 (USD Million)
  • 6.9. Other (Respiratory Disease, Diabetes)
    • 6.9.1. Other (including clinical trial) market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Drug Discovery Platforms Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2025 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Drug Discovery Platforms Market by End use Outlook
  • 7.4. Biopharmaceutical Companies
    • 7.4.1. Biopharmaceutical Companies market estimates and forecast 2021 to 2033 (USD Million)
  • 7.5. Academic and Research Institutes
    • 7.5.1. Academic and Research Institites market estimates and forecast 2021 to 2033 (USD Million)
  • 7.6. CROs/CDMO
    • 7.6.1. CROs/CDMO market estimates and forecast 2021 to 2033 (USD Million)

Chapter 8. Drug Discovery Platforms Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Regional Market Snapshot
  • 8.4. Market Size, Forecasts, & Trends Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.6.6. Sweden
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.6.7. Denmark
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.6.8. Norway
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.7.4. South Korea
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.7.5. Thailand
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.7.6. Australia
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Key Company Market Share Analysis, 2025 (%)
  • 9.4. Key Company Market Position Analysis, 2025
  • 9.5. Company Profiles
    • 9.5.1. Schrodinger, Inc.
      • 9.5.1.1. Company overview
      • 9.5.1.2. Financial performance
      • 9.5.1.3. Product benchmarking
      • 9.5.1.4. Strategic initiatives
    • 9.5.2. Certara
      • 9.5.2.1. Company overview
      • 9.5.2.2. Financial performance
      • 9.5.2.3. Product benchmarking
      • 9.5.2.4. Strategic initiatives
    • 9.5.3. Optibrium Ltd
      • 9.5.3.1. Company overview
      • 9.5.3.2. Financial performance
      • 9.5.3.3. Product benchmarking
      • 9.5.3.4. Strategic initiatives
    • 9.5.4. Insilico Medicine
      • 9.5.4.1. Company overview
      • 9.5.4.2. Financial performance
      • 9.5.4.3. Product benchmarking
      • 9.5.4.4. Strategic initiatives
    • 9.5.5. Atomwise, Inc.
      • 9.5.5.1. Company overview
      • 9.5.5.2. Financial performance
      • 9.5.5.3. Product benchmarking
      • 9.5.5.4. Strategic initiatives
    • 9.5.6. XtalPi Holdings Limited
      • 9.5.6.1. Company overview
      • 9.5.6.2. Financial performance
      • 9.5.6.3. Product benchmarking
      • 9.5.6.4. Strategic initiatives
    • 9.5.7. Dassault Systemes SE
      • 9.5.7.1. Company overview
      • 9.5.7.2. Financial performance
      • 9.5.7.3. Product benchmarking
      • 9.5.7.4. Strategic initiatives
    • 9.5.8. Genedata AG
      • 9.5.8.1. Company overview
      • 9.5.8.2. Financial performance
      • 9.5.8.3. Product benchmarking
      • 9.5.8.4. Strategic initiatives
    • 9.5.9. Relay Therapeutics, Inc.
      • 9.5.9.1. Company overview
      • 9.5.9.2. Financial performance
      • 9.5.9.3. Product benchmarking
      • 9.5.9.4. Strategic initiatives
    • 9.5.10. Recursion Pharmaceuticals, Inc.
      • 9.5.10.1. Company overview
      • 9.5.10.2. Financial performance
      • 9.5.10.3. Product benchmarking
      • 9.5.10.4. Strategic initiatives
    • 9.5.11. Merck KGaA
      • 9.5.11.1. Company overview
      • 9.5.11.2. Financial performance
      • 9.5.11.3. Product benchmarking
      • 9.5.11.4. Strategic initiatives
    • 9.5.12. insitro Inc.
      • 9.5.12.1. Company overview
      • 9.5.12.2. Financial performance
      • 9.5.12.3. Product benchmarking
      • 9.5.12.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global drug discovery platforms market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 5 Global drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 6 Global drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 7 Global drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 8 North America drug discovery platforms market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 10 North America drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 11 North America drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 12 North America drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 13 U.S. drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 14 U.S. drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 15 U.S. drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 16 U.S. drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 17 Canada drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 18 Canada drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 19 Canada drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 20 Canada drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Mexico drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 22 Mexico drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 23 Mexico drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 24 Mexico drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 25 Europe drug discovery platforms market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 27 Europe drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 28 Europe drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 29 Europe drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 30 UK drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 31 UK drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 32 UK drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 33 UK drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Germany drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 35 Germany drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 36 Germany drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 37 Germany drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 38 France drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 39 France drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 40 France drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 41 France drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 42 Italy drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 43 Italy drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 44 Italy drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 45 Italy drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 46 Spain drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 47 Spain drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 48 Spain drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 49 Spain drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Denmark drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 51 Denmark drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 52 Denmark drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 53 Denmark drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Sweden drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 55 Sweden drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 56 Sweden drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 57 Sweden drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 58 Norway drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 59 Norway drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 60 Norway drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 61 Norway drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific drug discovery platforms market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 67 China drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 68 China drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 69 China drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 70 China drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Japan drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 72 Japan drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 73 Japan drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 74 Japan drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 75 India drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 76 India drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 77 India drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 78 India drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 79 South Korea drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 80 South Korea drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 81 South Korea drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 82 South Korea drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Australia drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 84 Australia drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 85 Australia drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 86 Australia drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 87 Thailand drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 88 Thailand drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 89 Thailand drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 90 Thailand drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Latin America drug discovery platforms market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 93 Latin America drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 94 Latin America drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 95 Latin America drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 96 Brazil drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 97 Brazil drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 98 Brazil drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 99 Brazil drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 100 Argentina drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 101 Argentina drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 102 Argentina drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 103 Argentina drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 104 MEA drug discovery platforms market, by country, 2021 - 2033 (USD Million)
  • Table 105 MEA drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 106 MEA drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 107 MEA drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 108 MEA drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 109 South Africa drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 110 South Africa drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 111 South Africa drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 112 South Africa drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 117 UAE drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 118 UAE drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 119 UAE drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 120 UAE drug discovery platforms market, by end use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait drug discovery platforms market, by drug type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait drug discovery platforms market, by application, 2021 - 2033 (USD Million)
  • Table 123 Kuwait drug discovery platforms market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 124 Kuwait drug discovery platforms market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Drug discovery platforms market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Supply-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Market snapshot
  • Fig. 11 Segment outlook
  • Fig. 12 Segment outlook
  • Fig. 13 Competitive scenario
  • Fig. 14 Market dynamics
  • Fig. 15 Market driver relevance analysis (Current & future impact)
  • Fig. 16 Market restraint relevance analysis (Current & future impact)
  • Fig. 17 Drug discovery platforms market: Porter's five forces analysis
  • Fig. 18 Drug discovery platforms market: PESTLE analysis
  • Fig. 19 Drug discovery platforms drug type market: segment dashboard
  • Fig. 20 Drug discovery platforms drug type market: Market share analysis, 2025 & 2033
  • Fig. 21 Small molecule market, 2021 - 2033 (USD Million)
  • Fig. 22 Large molecule market, 2021 - 2033 (USD Million)
  • Fig. 23 Drug discovery platforms application market: Segment dashboard
  • Fig. 24 Drug discovery platforms market application: Market share analysis, 2025 & 2033
  • Fig. 25 Target identification market, 2021 - 2033 (USD Million)
  • Fig. 26 Target validation market, 2021 - 2033 (USD Million)
  • Fig. 27 Lead discovery market, 2021 - 2033 (USD Million)
  • Fig. 28 Lead optimization market, 2021 - 2033 (USD Million)
  • Fig. 29 Preclinical testing market, 2021 - 2033 (USD Million)
  • Fig. 30 Other (including clinical trials) market, 2021 - 2033 (USD Million)
  • Fig. 31 Drug discovery platforms therapeuitic area market: Segment dashboard
  • Fig. 32 Drug discovery platforms by therapeuitic area : Market share analysis, 2025 & 2033
  • Fig. 33 Oncology market 2021 - 2033 (USD Million)
  • Fig. 34 Neurology market 2021 - 2033 (USD Million)
  • Fig. 35 Cardiovascular diseases market 2021 - 2033 (USD Million)
  • Fig. 36 Infectious and immune system diseases market 2021 - 2033 (USD Million)
  • Fig. 37 Digestive system diseases market 2021 - 2033 (USD Million)
  • Fig. 38 Other (respiratory diseases, diabetes) market 2021 - 2033 (USD Million)
  • Fig. 39 Drug discovery platforms end use market: Segment dashboard
  • Fig. 40 Drug discovery platforms by end use: Market share analysis, 2025 & 2033
  • Fig. 41 Biopharmaceutical companies market 2021 - 2033 (USD Million)
  • Fig. 42 Academic and research institutes market 2021 - 2033 (USD Million)
  • Fig. 43 CROs/CDMO market 2021 - 2033 (USD Million)
  • Fig. 44 Drug discovery platforms market revenue, by region
  • Fig. 45 Regional key marketplace takeaway
  • Fig. 46 Regional key marketplace takeaway
  • Fig. 47 North America drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 U.S. Key country dynamics
  • Fig. 49 U.S. drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Canada Key country dynamics
  • Fig. 51 Canada drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Mexico Key country dynamics
  • Fig. 53 Mexico drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Europe drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 UK Key country dynamics
  • Fig. 56 UK drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Germany Key country dynamics
  • Fig. 58 Germany drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 France Key country dynamics
  • Fig. 60 France drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Italy Key country dynamics
  • Fig. 62 Italy drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Spain Key country dynamics
  • Fig. 64 Spain drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Denmark Key country dynamics
  • Fig. 66 Denmark drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Sweden Key country dynamics
  • Fig. 68 Sweden drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Norway Key country dynamics
  • Fig. 70 Norway drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Asia Pacific drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Japan Key country dynamics
  • Fig. 73 Japan drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 China Key country dynamics
  • Fig. 75 China drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 India Key country dynamics
  • Fig. 77 India drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Australia Key country dynamics
  • Fig. 79 Australia drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 South Korea Key country dynamics
  • Fig. 81 South Korea drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Thailand Key country dynamics
  • Fig. 83 Thailand drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Latin America drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Brazil Key country dynamics
  • Fig. 86 Brazil drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Argentina Key country dynamics
  • Fig. 88 Argentina drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 MEA drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 South Africa Key country dynamics
  • Fig. 91 South Africa drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Saudi Arabia Key country dynamics
  • Fig. 93 Saudi Arabia drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 UAE Key country dynamics
  • Fig. 95 UAE drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 96 Kuwait Key country dynamics
  • Fig. 97 Kuwait drug discovery platforms market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 98 Strategy Mapping
  • Fig. 99 Company market position analysis, 2025